LRCX vs PRLD · P/E 71, rev $23.23B vs rev $10.3M
Lam Research Corp (LRCX) versus Prelude Therapeutics Inc (PRLD) — a side-by-side from cached financials, not a winner call.
Lam Research Corp (LRCX) is a semiconductor equipment & materials company listed on NASDAQ.
Prelude Therapeutics Inc (PRLD) is a biotechnology company listed on NASDAQ.
Latest reported LRCX revenue for 2026-06-28 was $23.23B. Net income was $7.27B. Revenue was up 26.0% from 2025-06-29 to 2026-06-28. LRCX currently screens at market cap $467.94B and trailing P/E 70.9.
Latest reported PRLD revenue for 2026-06-30 was $10.3M. Net income was -$24.3M. PRLD currently screens at market cap $346.5M.
LRCX currently screens at market cap $467.94B and trailing P/E 70.9. PRLD currently screens at market cap $346.5M.
Not investment advice. Open the LRCX and PRLD stock pages for the full models.
Not investment advice.